Spruce Biosciences, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Spruce Biosciences, Inc. (SPRB) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $1.86 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2022-11-10
- Spruce Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-09-30 was $972.00K, a 50.46% decline year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-06-30 was $959.00K.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-03-31 was -$67.00K.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-12-31 was -$604.00K, a 30300.00% decline year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $1.15M, a 69.22% decline from fiscal 2020.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was $3.73M.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2019 was -$226.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2022-09-30 | $972.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.93M derived: sum of 2 quarters · filed 2022-11-10 | $1.86M 10-Q · filed 2022-11-10 | $1.26M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2022-06-30 | $959.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $892.00K 10-Q · filed 2022-08-10 | $288.00K derived: sum of 3 quarters · filed 2022-08-10 | $2.25M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2022-03-31 | -$67.00K 10-Q · filed 2022-05-11 | -$671.00K derived: sum of 2 quarters · filed 2022-05-11 | $1.29M derived: sum of 3 quarters · filed 2022-11-10 | $1.16M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-12-31 | -$604.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.36M derived: sum of 2 quarters · filed 2022-11-10 | $1.23M derived: sum of 3 quarters · filed 2022-11-10 | $1.15M 10-K · filed 2022-03-14 | |
| 2021-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.83M derived: sum of 2 quarters · filed 2022-11-10 | $1.75M 10-Q · filed 2022-11-10 | $1.83M 10-Q · filed 2021-11-15 | $1.75M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$209.00K 10-Q · filed 2022-08-10 | -$207.00K derived: sum of 3 quarters · filed 2022-08-10 | $1.27M derived: sum of 4 quarters · filed 2022-08-10 | |
| 2021-03-31 | -$82.00K 10-Q · filed 2022-05-11 | -$80.00K derived: sum of 2 quarters · filed 2022-05-11 | $1.40M derived: sum of 3 quarters · filed 2022-05-11 | $3.92M derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.48M derived: sum of 2 quarters · filed 2022-03-14 | $4.00M derived: sum of 3 quarters · filed 2022-03-14 | $3.73M 10-K · filed 2022-03-14 | |
| 2020-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $4.00M derived: sum of 2 quarters · filed 2021-11-15 | $3.73M 10-Q · filed 2021-11-15 | $3.64M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $2.26M 10-Q · filed 2021-08-10 | $2.17M derived: sum of 3 quarters · filed 2021-08-10 | ||
| 2020-03-31 | -$269.00K 10-Q · filed 2021-05-12 | -$358.00K derived: sum of 2 quarters · filed 2021-05-12 | |||
| 2019-12-31 | -$89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$226.00K 10-K · filed 2021-03-22 | |||
| 2019-09-30 | -$137.00K 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |